Can inflamed AD skin become a gateway for topical biologics? ➜ DOI: 10.34133/bmr.0368
Why it matters: A thermosensitive hyaluronic acid/Pluronic hydrogel delivered mesenchymal stromal cell-derived extracellular vesicles through AD-like lesional skin in mice, improving dermatitis scores, epidermal thickening, mast-cell infiltration, cytokine expression, barrier markers, and oxidative stress.
Context and caution: The most intriguing point is that damaged AD skin allowed EV penetration, partly dependent on EV surface proteins. This suggests a future “biologic patch” concept, but remains strictly preclinical, with no human AD data and major unresolved questions on manufacturing, dosing, safety, and reproducibility.
Bottom line: An imaginative preclinical paper for research-oriented readers, but still far from clinical topical biologics in AD.
Keratoconus and AD: should dermatologists ask about eye rubbing again? ➜ DOI: 10.1055/a-2815-9227
Why it matters: Keratoconus is rarely discussed in the AD field, although atopy – especially AD with ocular itch – is one of its best-known clinical associations. A new post-crosslinking cohort suggests that AD may remain a risk marker for keratoconus progression, although the signal is trend-level and based on small numbers.
Context and caution: This resonates with earlier Bordeaux work (DOI: 10.1159/000328408) showing frequent AD among keratoconus patients but no convincing shared filaggrin-mutation background, arguing against a simple common barrier-genetic explanation.
Bottom line: In AD patients with eyelid eczema, allergic conjunctivitis, or intense eye rubbing, dermatologists should think beyond the skin and encourage ophthalmologic assessment before irreversible corneal remodeling occurs.
Why it matters: In the ongoing debate on topical corticosteroid concerns and TSW, this study reminds us that some patients may have a conventional and testable problem: corticosteroid contact allergy. In 80 AD patients and 80 controls, hydrocortisone-17-butyrate allergy was more frequent in AD, but was detected only when tested in ethanol, not petrolatum.
Context and caution: Standard baseline markers, budesonide and tixocortol pivalate, were negative in all participants, and late readings improved detection. The study is small, but clinically relevant for selected refractory cases.
Bottom line: In persistent or apparently treatment-refractory AD, extended corticosteroid patch testing should be considered before attributing worsening to TSW or uncontrolled eczema alone.
Why it matters: This expert review summarizes the strengths and limitations of skin explants, human epidermal and skin equivalents, FLG-deficient models, cytokine-stimulated reconstructs, microbiome-containing systems, immune/neurosensory models, and emerging bioprinted or skin-on-chip approaches.
Context and caution: The key message is not that a single best AD model now exists. Model choice should depend on the question being asked: barrier biology, Th2 inflammation, microbiome interaction, drug screening, itch, or personalized medicine. Importantly, the authors acknowledge that no consensus yet exists on cytokine cocktails, concentrations, or timing of exposure.
Bottom line: A useful roadmap for research readers because it clarifies what still needs to be standardized before AD reconstructs can reliably support translational research.
Why it matters: At the ISAD-WHO meeting in Melbourne, patient testimonies reminded us that AD is not only visible eczema, itch, and sleep loss. It also affects work, school, relationships, mental health, daily activities, and the ability to live normally.
Context and caution: This Swedish study supports that message. In 112 adults with AD, DLQI scores correlated strongly with EQ-5D-5L utility values, a generic measure of overall health status used in health economic evaluation. A 5-point worsening in DLQI corresponded, on average, to a 0.07 reduction in EQ-5D-5L utility. The study is exploratory and based on a modest patient-association sample.
Bottom line: SCORAD remains the only established composite score assessing AD severity through objective signs, itch, and sleep loss. Adding DLQI offers a simple and widely available way to capture the broader global health burden of AD from the patient perspective.
Why it matters: Why does IL-31, the “itch cytokine”, share a receptor chain with oncostatin M? This human genetics study adds an important clue. Samra et al. report 10 patients from 7 unrelated families with biallelic loss-of-function variants in OSMR, encoding OSMRβ. All had early-onset severe atopic disease dominated by widespread treatment-resistant AD, high IgE, and eosinophilia.
Context and caution: Patient variants failed to localize normally to the cell surface. Patient fibroblasts showed impaired OSM-induced STAT1, STAT3, and STAT5 activation, while other GP130-dependent cytokine pathways were preserved. Re-expression of wild-type OSMR restored receptor expression and downstream signaling. The study still needs confirmation in additional patients, and the exact contribution of defective IL-31 versus OSM signaling remains to be clarified.
Bottom line: OSMRβ is not just a receptor accessory chain for IL-31-driven itch. Human OSMR loss-of-function points to a broader role in severe allergic inflammation and skin-barrier disease.
